- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2016
- Public Summary Document (PSD) March 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2016 PBAC Meeting - Word
Denosumab – March 2016
Denosumab: 120 mg/1.7 mL injection, 1 x 1.7 mL vial, XGEVA®
Last updated
15 July 2016